Davide Capodanno/X
Sep 4, 2025, 11:52
PARTHENOPE Trial: A New Benchmark in Risk Score Validation
Davide Capodanno, Professor of Cardiology at the University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on discrimination or area under the curve, but in reality, the true test of a score’s utility is whether randomization to a score-guided versus non–score-guided strategy makes a difference on clinical outcomes. Just think of how many scores we use every day that lack this kind of validation.”
Read more here.
Stay updated with Hemostasis Today.
-
May 7, 2026, 11:39Flora Peyvandi: Systematic Review of Genetic Findings in TTP
-
May 7, 2026, 11:03Ney Carter Borges: Oral Semaglutide and Cardiovascular Risk Factors in the SOUL Trial
-
May 7, 2026, 11:01Daniel Ben-Mordechay: Portal Vein Thrombosis – Ultrasound Perspective
-
May 7, 2026, 07:48Could Albuminuria Be an Overlooked Marker of Thrombotic Risk? – RPTH Journal
-
May 7, 2026, 07:37Matías J Alet: On the Implementation of Tenecteplase for Acute Ischemic Stroke at ESOC 2026
-
May 7, 2026, 07:21Britta Diebel: Reflections on Healthcare Impact from the PPTA IPPC Congress
-
May 7, 2026, 07:02Ana Cláudia de Souza: NeuroLeadership, Management and Behavioural Insights in Stroke Care from ESOC 2026
-
May 7, 2026, 07:00Maxime Dely: Just 60 Minutes of Our Time to Help a Patient We Will Never Meet
-
May 7, 2026, 06:37Anagha Kulkarni: Insights and A Prize from ISBMT Annual Conference 2026